The observed changes confirm the huge role of the excessive activity of the RAS-RAF-MEK-ERK and PI3K-Akt/PKB-mTOR pathways in the resistance of gliomas to the applied therapy (Steelman et al. 2011). This evidence concerns the gene MTOR and central nervous system cancer.